Literature DB >> 24067299

ΔFosB induction in prefrontal cortex by antipsychotic drugs is associated with negative behavioral outcomes.

David M Dietz1, Pamela J Kennedy2, Haosheng Sun2, Ian Maze3, Amy M Gancarz4, Vincent Vialou2, Ja Wook Koo2, Ezekiell Mouzon2, Subroto Ghose5, Carol A Tamminga5, Eric J Nestler2.   

Abstract

ΔFosB, a FosB gene product, is induced in the prefrontal cortex (PFC) by repeated exposure to several stimuli including antipsychotic drugs such as haloperidol. However, the functional consequences of increased ΔFosB expression following antipsychotic treatment have not been explored. Here, we assessed whether ΔFosB induction by haloperidol mediates the positive or negative consequences or clinical-related actions of antipsychotic treatment. We show that individuals with schizophrenia who were medicated with antipsychotic drugs at their time of death display increased ΔFosB levels in the PFC, an effect that is replicated in rats treated chronically with haloperidol. In contrast, individuals with schizophrenia who were medication-free did not exhibit this effect. Viral-mediated overexpression of ΔFosB in the PFC of rodents induced cognitive deficits as measured by inhibitory avoidance, increased startle responses in prepulse inhibition tasks, and increased MK-801-induced anxiety-like behaviors. Together, these results suggest that ΔFosB induction in the PFC by antipsychotic treatment contributes to the deleterious effects of these drugs and not to their therapeutic actions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24067299      PMCID: PMC3895248          DOI: 10.1038/npp.2013.255

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  37 in total

Review 1.  Animal models of neuropsychiatric disorders.

Authors:  Eric J Nestler; Steven E Hyman
Journal:  Nat Neurosci       Date:  2010-09-27       Impact factor: 24.884

Review 2.  Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.

Authors:  S Miyamoto; N Miyake; L F Jarskog; W W Fleischhacker; J A Lieberman
Journal:  Mol Psychiatry       Date:  2012-05-15       Impact factor: 15.992

Review 3.  Neurobiology of treatment-resistant schizophrenia: new insights and new models.

Authors:  L J Beerpoot; B K Lipska; D R Weinberger
Journal:  Eur Neuropsychopharmacol       Date:  1996       Impact factor: 4.600

Review 4.  Neuropeptide regulation of fear and anxiety: Implications of cholecystokinin, endogenous opioids, and neuropeptide Y.

Authors:  Mallory E Bowers; Dennis C Choi; Kerry J Ressler
Journal:  Physiol Behav       Date:  2012-03-10

Review 5.  Modeling madness in mice: one piece at a time.

Authors:  P Alexander Arguello; Joseph A Gogos
Journal:  Neuron       Date:  2006-10-05       Impact factor: 17.173

Review 6.  Cortical interneurons, immune factors and oxidative stress as early targets for schizophrenia.

Authors:  Patricio O'Donnell
Journal:  Eur J Neurosci       Date:  2012-06       Impact factor: 3.386

7.  Effects of inhibitor of κB kinase activity in the nucleus accumbens on emotional behavior.

Authors:  Daniel J Christoffel; Sam A Golden; Mitra Heshmati; Ami Graham; Shari Birnbaum; Rachael L Neve; Georgia E Hodes; Scott J Russo
Journal:  Neuropsychopharmacology       Date:  2012-07-11       Impact factor: 7.853

8.  Cocaine dynamically regulates heterochromatin and repetitive element unsilencing in nucleus accumbens.

Authors:  Ian Maze; Jian Feng; Matthew B Wilkinson; HaoSheng Sun; Li Shen; Eric J Nestler
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-07       Impact factor: 11.205

9.  Regulation of gene expression and cocaine reward by CREB and DeltaFosB.

Authors:  Colleen A McClung; Eric J Nestler
Journal:  Nat Neurosci       Date:  2003-10-19       Impact factor: 24.884

Review 10.  Group II metabotropic glutamate receptors and schizophrenia.

Authors:  José L Moreno; Stuart C Sealfon; Javier González-Maeso
Journal:  Cell Mol Life Sci       Date:  2009-08-26       Impact factor: 9.261

View more
  5 in total

1.  ΔFOSB: A Potentially Druggable Master Orchestrator of Activity-Dependent Gene Expression.

Authors:  Alfred J Robison; Eric J Nestler
Journal:  ACS Chem Neurosci       Date:  2022-01-12       Impact factor: 4.418

Review 2.  Neurogenetic and epigenetic correlates of adolescent predisposition to and risk for addictive behaviors as a function of prefrontal cortex dysregulation.

Authors:  Kenneth Blum; Marcelo Febo; David E Smith; A Kenison Roy; Zsolt Demetrovics; Frans J Cronjé; John Femino; Gozde Agan; James L Fratantonio; Subhash C Pandey; Rajendra D Badgaiyan; Mark S Gold
Journal:  J Child Adolesc Psychopharmacol       Date:  2015-04-28       Impact factor: 2.576

Review 3.  Epigenetic Basis of Mental Illness.

Authors:  Eric J Nestler; Catherine J Peña; Marija Kundakovic; Amanda Mitchell; Schahram Akbarian
Journal:  Neuroscientist       Date:  2015-10-08       Impact factor: 7.519

4.  Cannabidiol attenuates sensorimotor gating disruption and molecular changes induced by chronic antagonism of NMDA receptors in mice.

Authors:  Felipe V Gomes; Ana Carolina Issy; Frederico R Ferreira; Maria-Paz Viveros; Elaine A Del Bel; Francisco S Guimarães
Journal:  Int J Neuropsychopharmacol       Date:  2014-10-31       Impact factor: 5.176

5.  Δ9-Tetrahydrocannabinol Experience Influences ΔFosB and Downstream Gene Expression in Prefrontal Cortex.

Authors:  Matthew F Lazenka; Minho Kang; Dipanjana Datta De; Dana E Selley; Laura J Sim-Selley
Journal:  Cannabis Cannabinoid Res       Date:  2017-08-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.